ClostraBio, a biotech company that makes next-generation probiotics for gut health, shared some big updates. They launched their first product with Designs for Health, started a human clinical study on their main probiotic, Anaerostipes caccae CLB101, and will be at SupplySide Global. These steps are important for the company’s mission to offer proven probiotics to healthcare professionals and customers.
Health Technology Insights: Cycle Pharmaceuticals Launches PHYRAGO Tablets in US for Oncology
Their first product with CLB101 is now available through Designs for Health, a well-known company that sells science-backed supplements through healthcare providers. This partnership shows ClostraBio’s dedication to working with companies that value strong scientific standards and education for healthcare professionals.
Ritu Shah, the CEO of ClostraBio, said they are happy to partner with Designs for Health to bring CLB101 to the market. She explained that both companies share a strong belief in products that are backed by science and maintain scientific integrity, which made Designs for Health the perfect choice for their first commercial effort.
Health Technology Insights: Color Health, Google Cloud Team Up to Boost Breast Cancer Screening
ClostraBio is also running a 48-person clinical trial to check the safety and how well CLB101 is tolerated. They are also looking into how it might help with gut health and strengthen the intestinal lining. The trial is moving quickly, showing how much interest there is in next-gen probiotics and the need for effective supplements that support gut function. Brian Meehan, the company’s Chief Scientific Officer, said the trial reflects ClostraBio’s focus on understanding how CLB101 affects gut barrier health and the overall consumer experience.
In addition to the product launch and the study, ClostraBio will be at SupplySide Global from October 27 to 30 to share their progress, connect with partners, and push for innovation in the probiotics field. Ritu Shah was also chosen as a SupplySide Global advocate for 2025 and appeared in a video talking about the event’s importance. ClostraBio continues to use science and biotechnology to develop probiotics that make butyrate in the lower gut, boosting barrier function and keeping the gut microbiome balanced. CLB101 has received self-affirmed GRAS status and is now sold in the U.S. as a dietary supplement.
Health Technology Insights: IntrinsiQ Enhances Data Tools to Boost Patient Outcomes
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
